DUBLIN--(BUSINESS WIRE)--The "Peanut Allergy Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
The study analyzed that peanut allergy therapeutics pipeline comprises approximately 19 drug candidates in different stages of development.
According to the research findings, a majority of the drug candidates for the treatment of peanut allergy are being developed to be administered by the oral route which is convenient to take, and has been considered as non-invasive, and is often a safer route that requires no special training to be given to the patients.
It has been observed that most of the companies are developing drug candidates by using advanced technologies and the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, BioLingus Inc. is utilizing its technology, BioLingus technology, which is a micro-encapsulation process, that delivers macro molecules such as peptides and proteins and is particularly effective for sublingual immunotherapy. With this technology, it has been observed in the Pre-Clinical models that sublingual IL-2 is found efficacious in 500th times lower amount than the investigational sublingual IL-2 therapy for the treatment of peanut allergy.
Some of the key players involved in the development of peanut allergy therapeutics include Aimmune Therapeutics Inc., DBV Technologies S.A., and AnaptysBio Inc.
Key Topics Covered
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. Peanut allergy Therapeutics Pipeline Analysis by Phase (2018)
6. Clinical Trials Review
7. Competitive Landscape
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/q5bxzf/global_peanut?w=4